Jun 17, 2018 10:05 PM
https://www.nature.com/articles/d41586-018-05461-x
EXCERPT: . . . The agency's decision, announced on 15 June, came shortly after an NIH advisory council voted unanimously to end the trial. An agency investigation had found that NIH staff and outside researchers acted inappropriately by soliciting industry funding and biasing the grant review process to favor specific scientists.
Those findings have undermined the study's credibility if it had been allowed to proceed, said NIH director Francis Collins at the advisory-council meeting. “Is it even possible at this point that the results of this trial would have the credibility to influence anyone’s decision-making,” he asked. “That does in fact seem quite doubtful.”
MORE: https://www.nature.com/articles/d41586-018-05461-x
~
EXCERPT: . . . The agency's decision, announced on 15 June, came shortly after an NIH advisory council voted unanimously to end the trial. An agency investigation had found that NIH staff and outside researchers acted inappropriately by soliciting industry funding and biasing the grant review process to favor specific scientists.
Those findings have undermined the study's credibility if it had been allowed to proceed, said NIH director Francis Collins at the advisory-council meeting. “Is it even possible at this point that the results of this trial would have the credibility to influence anyone’s decision-making,” he asked. “That does in fact seem quite doubtful.”
MORE: https://www.nature.com/articles/d41586-018-05461-x
~